Atrial Fibrillation
Atrial fibrillation (AF) is a heart condition characterized by an irregular and often rapid heartbeat, which can lead to poor blood flow and increase the risk of stroke and heart-related complications.
We are studying whether abelacimab can help high-risk patients with atrial fibrillation who cannot take oral blood thinners. The goal is to see if it reduces the risk of strokes and other serious complications compared to a placebo.
Health conditions and diseases that the clinical trial is designed to study and treat.
Atrial fibrillation (AF) is a heart condition characterized by an irregular and often rapid heartbeat, which can lead to poor blood flow and increase the risk of stroke and heart-related complications.
These questions help us understand your situation so we can let the trial team know whether you might be a potential match. This is not a medical evaluation and is not part of the official screening, the study doctor will make the final decision..
Experimental substances that are being investigated in this clinical trial. These are not yet approved for general use.
Locations and medical facilities where this clinical trial is currently recruiting or conducting research. Select the locations where you would like to participate.
Disclaimer: Parts of this content have been automatically extracted from the EU Clinical Trials registry. While we strive for accuracy, please always contact the trial site or sponsor directly for correct and official information before making any decisions about participation. View on EU Clinical Trials.